Can Biomarkers Guide Oncolytic Virus Immunotherapy?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33849964.
- Also identified by DOI 10.1158/1078-0432.CCR-21-0660.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Defects in tumor cell IFNγ signaling is associated with resistance to immune checkpoint inhibitors. Recently, these defects were found to confer increased sensitivity to oncolytic virus infection. Differential expression of innate sensing elements in tumor cells may serve as predictive biomarkers of oncolytic virus immunotherapy in patients with cancer.<i>See related article by Nguyen et al., p. 3432</i>.
Medical subject headings
- Neoplasms
- Oncolytic Virotherapy
- Oncolytic Viruses